The Exchange had sought clarification from Beta Drugs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited reported strong FY25 consolidated results with total revenue of Rs 368.8 crores, up 24.14% from Rs 297.1 crores in FY24, driven by 25.28% growth in its Own Brands segment. Consolidated EBITDA stood at Rs 81.04 crores (margin: 22.37%), with the Oncology segment delivering 24.03% EBITDA margins. Net profit before exceptional items grew 25.78% to Rs 45.83 crores; after factoring in Rs 4.57 crores of one-time expenses linked to a Nov 2024 preferential issue, reported net profit was Rs 42.41 crores (EPS Rs 42.02). The company also secured COFEPRIS approval for its Adley Labs API facility and is targeting FY26 revenue above Rs 450 crores with EBITDA margins of 23-25%. The filing also addresses a minor NSE query on the format of submitted financial results, which the company has now clarified. Auditor Khurana Sharma & Co. issued an unmodified (clean) opinion on both standalone and consolidated results.
Strong double-digit revenue and profit growth, expanding margins in the core Oncology business, and a clean audit opinion are positive signals for shareholders. However, the sharp rise in long-term borrowings (from Rs 6 crores to Rs 127 crores) due to the preferential issue and the Rs 4.57 crore exceptional charge slightly temper the headline profitability picture.